Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: SUSTIVA

« Back to Dashboard
Sustiva is a drug marketed by Bristol Myers Squibb and is included in two NDAs. It is available from two suppliers. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in SUSTIVA is efavirenz. There are twenty-two drug master file entries for this compound. Two suppliers are listed for this compound. There are twenty-six tentative approvals for this compound. Additional details are available on the efavirenz profile page.

Clinical Trials for: SUSTIVA

Sustiva Levels With Use of a Gel Capsule
Status: Completed Condition: HIV; HIV Infections

Modification of Doses of Efavirenz According to Its Blood Concentration in HIV Patients
Status: Completed Condition: HIV

Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CYP3A4, UGT1A1, ABCB1 and ABCC2
Status: Completed Condition: Pharmacokinetics; Drug Interactions; Pharmacodynamics; Intestinal Transporter Expression

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
Status: Active, not recruiting Condition: Hyperlipidemia; HIV

Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers
Status: Active, not recruiting Condition: Healthy Volunteers

Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics
Status: Completed Condition: HIV

Efavirenz Comparative Bioavailability
Status: Completed Condition: Healthy

Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
Status: Completed Condition: Healthy

GSK1349572 Drug Interaction Study With Efavirenz
Status: Completed Condition: Infections, Human Immunodeficiency Virus and Herpesviridae; Healthy

Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg
Status: Terminated Condition: Tuberculosis; HIV Infections

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
CAPSULE;ORAL020972-001Sep 17, 1998RXNo6,939,964*PED<disabled>Y<disabled>
Bristol Myers Squibb
CAPSULE;ORAL020972-003Sep 17, 1998RXYes<disabled><disabled>
Bristol Myers Squibb
TABLET;ORAL021360-002Feb 1, 2002RXYes6,639,071*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: SUSTIVA

Drugname Dosage Strength RLD Submissiondate
efavirenzTablets600 mgSustiva4/9/2009
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn